# Clinical impact of prophylactic antibiotics in kidney transplantation: A retrospective observational cohort study with historical comparison

**Authors:** Sang Ah Lee, Jin-Myung Kim, Hye Eun Kwon, Youngmin Ko, Joo Hee Jung, Sung Shin, Young Hoon Kim, Sung-Han Kim, Hyunwook Kwon

PMC · DOI: 10.1371/journal.pone.0337578 · PLOS One · 2025-11-21

## TL;DR

A study comparing two antibiotic regimens in kidney transplant patients found that a single dose of cefazolin may increase urinary tract infections but reduce acute rejection rates.

## Contribution

This study provides clinical evidence comparing the efficacy of ampicillin/sulbactam and cefazolin in kidney transplantation outcomes.

## Key findings

- The cefazolin group had a higher tendency for urinary tract infections (3.4% vs. 2.2%) after transplantation.
- The cefazolin group had significantly lower 6-month acute rejection rates (5.1% vs. 7.9%).
- Cefazolin was significantly associated with reduced acute rejection in multivariable analysis (odds ratio 0.63).

## Abstract

Optimal perioperative antibiotic prophylaxis in kidney transplantation remains undefined despite routine antibiotic administration to prevent infections. In this retrospective observational cohort study with historical comparison, we compared the clinical efficacy of 6 days of ampicillin/sulbactam vs. a single dose of cefazolin.

We retrospectively analyzed 2322 kidney transplantation recipients at a single center, with the evaluation period spanning from 2015 through 2021. Patients were divided into 2 groups based on the perioperative antibiotic regimen received: 971 patients received ampicillin/sulbactam, and 1351 received cefazolin. This study focused on evaluating the impact of these regimens on postoperative infection incidence and the 6-month acute rejection (AR) rates.

The cefazolin group exhibited a tendency toward higher urinary tract infection rates within 1 month after transplantation (3.4% vs. 2.2%, p= = 0.078). There were no significant differences in surgical site infections between the groups. The 6-month AR rates were significantly lower in the cefazolin group than in the ampicillin/sulbactam group (5.1% vs. 7.9%, p= = 0.009). Cefazolin was also confirmed to be significantly associated with reduced 6-month AR rates in the multivariable logistic regression analysis (odds ratio 0.63, 95% confidence interval [0.45-0.89], p= = 0.009).

In this study, we observed that a single dose of cefazolin as perioperative antibiotic prophylaxis may lead to higher rates of postoperative urinary tract infections, but it could potentially lower the incidence of acute rejection within six months.

## Linked entities

- **Chemicals:** ampicillin/sulbactam (PubChem CID 119561), cefazolin (PubChem CID 33255)
- **Diseases:** urinary tract infection (MONDO:0005247)

## Full-text entities

- **Diseases:** infection (MESH:D007239), urinary tract infection (MESH:D014552)
- **Chemicals:** ampicillin/sulbactam (MESH:C035444), Cefazolin (MESH:D002437)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12637934/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12637934/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12637934/full.md

---
Source: https://tomesphere.com/paper/PMC12637934